(firstQuint)A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis.

 Twelve patients aged 18-80 with symptomatic generalized autoimmune MG that are not being treated with medication that suppresses their immune system, other than prednisone, will enter the study at UIC over a two year period.

 The study will involve a screening visit and visits at baseline and at days 5, 15, 30, 45, 60, 90, and 120.

 The study drug, Leukine (GM-CFS), is given by injection.

 Subjects will give themselves one dose of GM-CSF every day for 10 days.

 Study visits will include muscle testing, immunologic studies and quality-of-life studies.

.

 A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis@highlight

The purpose of this study is to determine whether the drug Leukine (GM-CFS) is safe and tolerated by patients with autoimmune myasthenia gravis (MG).

